Loading…
Employees: 1,078
Size Beijing Chunlizhengda Medical Instruments (1858.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $671M, the 685th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$7.69 on 6 Nov 2026.
Performance Over six months the shares fell 27.4%, against -7.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 9.0% over the last twelve months (peer median +14.0%); the operating margin is 30.7% (peer median 11.7%).
Valuation It trades at 9.2× forward earnings against a peer median of 21.2× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.4 points above its cost of capital (8.2% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.04B | HK$1.13B | HK$867M | HK$1.32B | HK$1.39B |
| Revenue growth | — | +30% | -34% | -5% | — |
| Gross profit | HK$679M | HK$712M | HK$551M | HK$931M | HK$1.03B |
| EBITDA | n/a | HK$334M | HK$136M | HK$323M | HK$358M |
| Net income | HK$305M | HK$296M | HK$136M | HK$307M | HK$358M |
| Free cash flow | HK$360M | HK$392M | -HK$33.0M | HK$553M | HK$50.4M |
| Capital expenditure | HK$48.5M | HK$64.1M | HK$53.3M | HK$36.7M | HK$29.0M |
| Total debt | HK$2.80M | HK$4.20M | HK$978,049 | HK$14.1M | HK$20.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1858.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.6% | -1.4% | 8th highest of 21 |
| 6-month return | -27.4% | -7.8% | 5th lowest of 21 |
| Distance from 52-week high | -63.1% | -25.7% | 4th lowest of 21 |
| Revenue growth (TTM) | -9.0% | +14.0% | 4th lowest of 21 |
| Operating margin | 30.7% | 11.7% | 3rd highest of 21 |
| Forward P/E | 9.2× | 21.2× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -8.0% | 1.7% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +1.5% | +14.2% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | -9.5 pp | -12.6 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +18.4 pp | -0.2 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $671M | -27% | -9% | 31% | 9.2× | -8.0% | +1.5% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |